LBPMedicine(SH:688393)2021-04-27 16:00Financial Performance - Operating revenue surged by 158.72% to CNY 99,508,003.08 year-on-year[7] - Net profit attributable to shareholders increased by 169.87% to CNY 26,664,570.54 compared to the same period last year[7] - Basic earnings per share rose by 107.14% to CNY 0.29[7] - The company's operating revenue for Q1 2021 reached ¥99,508,003.08, representing a 158.72% increase compared to ¥38,461,902.33 in Q1 2020, primarily due to a significant increase in sales volume[14] - Net profit for Q1 2021 was ¥26,233,758.61, representing a 189.5% increase from ¥9,064,366.31 in Q1 2020[29] - Net profit for Q1 2021 was ¥21,729,658.91, representing a 143.5% increase from ¥8,942,163.07 in Q1 2020[32] Cash Flow - Net cash flow from operating activities improved significantly to CNY 1,564,154.14, compared to a negative CNY 2,207,715.69 in the previous year[7] - The net cash flow from operating activities improved to ¥1,564,154.14, a significant recovery from a negative cash flow of -¥2,207,715.69 in Q1 2020, driven by increased sales collections and government subsidies[14] - The company recorded a net increase in cash and cash equivalents of ¥27,720,827.30 in Q1 2021, contrasting with a decrease of ¥22,129,118.89 in Q1 2020[36] - The company reported a cash flow from operating activities of ¥1,564,154.14, a turnaround from a negative cash flow of ¥2,207,715.69 in Q1 2020[36] Assets and Liabilities - Total assets increased by 1.94% to CNY 1,317,292,767.74 compared to the end of the previous year[7] - The company's total assets amounted to 1,317.29 million CNY, an increase from 1,292.25 million CNY at the end of 2020[22] - The company's total current assets reached 1,073.81 million CNY, compared to 1,062.92 million CNY at the end of 2020, reflecting a growth of approximately 1.7%[20] - The company's total liabilities decreased by 60.90% in employee compensation payable, dropping to ¥5,496,480.43 from ¥14,058,838.44, reflecting the impact of year-end bonus provisions from the previous year[13] - Total liabilities increased to ¥141,989,765.76 from ¥139,333,798.27, a rise of 1.2%[26] Shareholder Information - The total number of shareholders reached 7,956 by the end of the reporting period[10] - The largest shareholder, Cai Xiangting, holds 21.23% of the shares, totaling 19,817,000 shares[10] Research and Development - R&D expenditure as a percentage of operating income decreased by 4.95 percentage points to 6.10%[7] - Research and development expenses increased by 42.81% to ¥6,071,613.10 from ¥4,251,649.33, indicating a focus on enhancing product development[14] - Research and development expenses for Q1 2021 were ¥6,071,613.10, compared to ¥4,251,649.33 in Q1 2020, an increase of 43.0%[28] Tax and Other Expenses - The company’s tax expenses rose by 202.02% to ¥5,021,825.47 from ¥1,662,723.83, reflecting increased profitability[14] - Sales expenses increased to ¥31,769,298.09 in Q1 2021, compared to ¥8,376,673.96 in Q1 2020, reflecting expanded marketing efforts[32] Incentive Plans - The company approved a restricted stock incentive plan to grant 2.00 million shares, representing 2.14% of the total share capital, with an initial grant of 1.70 million shares (1.82% of total share capital) and a reserve of 0.30 million shares (0.32% of total share capital) [15] - The first grant date for the restricted stock was set for February 8, 2021, with a grant price of 31.00 CNY per share for 170.30 thousand shares to 129 incentive recipients [16]